We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.30 | 1.20 | 1.40 | 1.30 | 1.30 | 1.30 | 30,885 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2018 13:58 | Nice come back...plenty more to come this week..12p looks good | georgie pie | |
24/4/2018 13:55 | This is a good take from Lunatic Asylum :- Today 13:28 Jediknight RE: Traders and liars-Doc H 8.10 No Opinion So is there any credence to the fact that no speeding ticket issued yesterday re 50% rise? | the stigologist | |
24/4/2018 13:53 | I like their emphasis on Personalised Medicine ahead of tomorrows big Innovate UK Personalised Medicine Accelerator launch... at BioTrinity | the stigologist | |
24/4/2018 13:48 | Brilliant stig thanks.. Just shows where we are and where we are going.. Way undervalued | shirley83 | |
24/4/2018 13:44 | So here for those who couldn't see some of the highlights in the Presentation Slides is my summary :- "Predicting Efficacy of Anti-Cancer Regimes in the Brave New World of Immunotherapy and Personalised Medicine" Physiomics has successfully completed over 50 projects with clients/partners - Big Pharma (Lilly, Merck, Bayer, Undisclosed Clients) - Grants (TEMPO, Green Biologics, Technology Strategy Board/InnovateUK) - Biotechs (Cyclacel, Sareum, Undisclosed Clients) - Academic (University of Oxford, Swansea University, Institute of Cancer Research, Cancer Research Technology) Recent Successes Nov 2017 - Merck Master Services Agreement Jan 2018 - New Big Pharma Client Feb 2018 - New Big Pharma Client Mar 2018 - New Innovate UK grant for Personalised Medicine We Offer In-Silico Modelling For All Stages of R&D with Focus on Pre-Clinical and Clinical 'Currently working on a number of Immune-oncology focused...' | the stigologist | |
24/4/2018 13:33 | Be patient and this will finish Blue today!!!!All imho.dyor. | miahkaysor | |
24/4/2018 12:59 | Nice shake out this morning onwards and upwards | hope67 | |
24/4/2018 12:55 | No one cares bout your twitter stig shut your mouth ... don't sound nice does it. Idiot | bauchsapt | |
24/4/2018 12:50 | It's ok he struggles to be calm and will be calling obscenities before you know it for nothing | markth126 | |
24/4/2018 12:47 | Nice slides depicting a simple but massive story | the stigologist | |
24/4/2018 12:44 | If it gets to 9p watch the fireworks | shirley83 | |
24/4/2018 12:41 | Calm down it's just a question | bauchsapt | |
24/4/2018 12:29 | The company update by DR jim was that supposed to be an RNS to investors or at biotrinity presentation? | bauchsapt | |
24/4/2018 12:20 | A nice bowl formation to 15p forming.. | shirley83 | |
24/4/2018 12:16 | Needs a little push now and this will move nice imo | margic | |
24/4/2018 12:12 | Double figures this afternoon.. Tomorrow whoosh | shirley83 | |
24/4/2018 12:10 | Oufff, next step coming imo. | margic | |
24/4/2018 12:09 | Looks very very ready for me now technically. That 240 chart complementing monthly and weekly beautiful, low test daily, that flips blue could be a very big green bar added to today's daily... | margic | |
24/4/2018 12:03 | Looking like a strong afternoon push for sure | letmepass | |
24/4/2018 12:03 | Volumes gonna pass 10mil today, lunch is upon us | margic | |
24/4/2018 11:45 | Blue day coming and 12p to buy | shirley83 | |
24/4/2018 11:34 | The large spread failing to deter buyers. Always a good sign. | hazelst |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions